Acam2000 Injection, Powder, Lyophilized, For Solution
Product Images NDC 71665-330

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Acam2000 (NDC 71665-330). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Emergent Product Development Gaithersburg Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Acam Vial Label.jpg (Acam Vial Label)

Label for Diluent for ACAM2000 solution, a diluent for the ACAM2000 smallpox and mpox (vaccinia) vaccine, live. The label warns it is for strategic national stockpile use only and specifies storage at 2-8°C with use within 30 days after reconstitution. Manufactured by Emergent Product Development Gaithersburg Inc., it states percutaneous use with a bifurcated needle and contains lot, manufacturing, and reconstitution date fields.*

FDA Label Image

M:\ra\ectd\spl\labels\acam\april 2018\medguide Image 1 Expected Response.jpg (Image 01)

A series of three sequential close-up images illustrating a skin lesion progressing through different stages, likely related to a reaction caused by the Diluent for ACAM2000 vaccine. Each image shows increasing size and development of the lesion on the skin.*

FDA Label Image

Medguide Image 1 Infected Arm.jpg (Image 02)

FDA Label Image

Medguide Image 2 Infected Eye.jpg (Image 03)

FDA Label Image

Acam Carton Label.jpg (Image 04)

Label for Smallpox (Vaccinia) Vaccine, Live ACAM2000, a percutaneous vaccine containing live vaccinia virus with potency 1-5 x 10^8 PFU/mL. It is for use with a bifurcated needle and contains 50 vials, each with 0.3 mL/100 doses. Manufactured by Emergent Product Development Gaithersburg Inc., USA.*

FDA Label Image

Images Of The Expected Cutaneous Reaction From Day 3 To Day 14 After Revaccination Showing Modified (reduced) Reaction Compared To Primary Vaccination. (Rad643fe.tmp 00.jpg)

A four-panel photographic series showing the progression of skin reactions on an upper arm, illustrating changes in redness and lesion size over time after vaccination. The images focus on the localized area of injection, demonstrating the evolving skin response characteristic of percutaneous vaccination application.*

FDA Label Image

Images Of The Expected Cutaneous Reaction After Primary Vaccination Showing Progression From A Vesicle (day 5) To A Pustule (days 8-10) To A Scab (day 14). (Rad643fe.tmp 01.jpg)

A photographic illustration showing four close-up images of a skin lesion at different stages of progression, likely related to percutaneous vaccine administration site reactions. The images depict changes in lesion appearance from a raised, white scab with surrounding redness to a larger dark scab with some tissue breakdown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.